Calendrier des promotions Anixa Biosciences, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Anixa Biosciences, Inc.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Paramètres de base
IPO date
1987-01-01
ISIN
US03528H1095
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 470.6 | 1 |
P/BV | 6.7 | 1 |
P/E | 0 | 0 |
Efficacité
Nom | Signification | Grade |
ROA | -53.29 | 0 |
ROE | -56.63 | 0 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0 | 0 |
DSI | 0 | 0 |
Croissance moyenne du dividende | 0 | 0 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | -0.0183 | 10 |
Debt/Ratio | 0.0107 | 10 |
Debt/Equity | 0.1431 | 10 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | -80.91 | 0 |
Rentabilité Ebitda, % | 30.53 | 5 |
Rentabilité EPS, % | -14.9 | 0 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 3.34 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 3.42 $ | 0 $ | 0 $ | -2.2 % | 0 % | 0 % |
common.calendar.number_days.30d | 2.5 $ | 2.76 $ | 3.6 $ | 33.6 % | 0 % | 0 % |
common.calendar.number_days.90d | 2.58 $ | 2.38 $ | 3.6 $ | 29.46 % | 0 % | 0 % |
common.calendar.number_days.180d | 3.16 $ | 2.13 $ | 3.6 $ | 5.7 % | 0 % | 0 % |
common.calendar.number_days.1y | 3.29 $ | 2.13 $ | 3.97 $ | 1.52 % | 0 % | 0 % |
common.calendar.number_days.3y | 4.07 $ | 2.13 $ | 6.15 $ | -17.94 % | 0 % | 0 % |
common.calendar.number_days.5y | 2.88 $ | 1.79 $ | 7.14 $ | 15.97 % | 0 % | 0 % |
common.calendar.number_days.10y | 0.6001 $ | 0.6001 $ | 7.14 $ | 556.57 % | 0 % | 0 % |
common.calendar.number_days.ytd | 2.8 $ | 2.13 $ | 3.6 $ | 19.29 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
Superviseur | Titre d'emploi | Paiement | Année de naissance |
Dr. Amit Kumar Ph.D. | CEO, Chairman & Co-Chair of CBAB | 1.29M | 1964 (61 année) |
Mr. Michael J. Catelani CPA, MBA | President, COO, CFO & Corporate Secretary | 788.83k | 1967 (58 années) |
Mr. John Roop | Senior Vice President of Engineering | 275k | 1950 (75 années) |
Dr. Pamela D. Garzone Ph.D. | Chief Development Officer & Chair Breast Cancer Clinical Advisory Board | 1955 (70 années) |
Informations sur l'entreprise
Adresse: United States, San Jose. CA, 3150 Almaden Expressway - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.anixa.com
Site web: https://www.anixa.com